5/16/2025

Imatinib Mesylate Tablets

Products Affected - Description

- Imatinib mesylate oral tablet, Apotex, 100 mg, bottle, 90 count, NDC 60505-2900-09
- Imatinib mesylate oral tablet, Apotex, 400 mg, bottle, 30 count, NDC 60505-2901-03
- Imatinib mesylate oral tablet, Major, 400 mg, unit-dose blister pack, 30 count, NDC 00904-6621-04
- Imatinib mesylate oral tablet, Teva, 100 mg, bottle, 90 count, NDC 00093-7629-98
- Imatinib mesylate oral tablet, Teva, 400 mg, bottle, 30 count, NDC 00093-7630-56
- Imatinib mesylate oral tablet, Upsher-Smith, 100 mg, bottle, 90 count, NDC 00832-0532-09
- Imatinib mesylate oral tablet, Upsher-Smith, 400 mg, bottle, 30 count, NDC 00832-0533-03

Reason for the Shortage

- Apotex did not provide a reason for the shortage.
- Chartwell has imatinib tablets available.
- Major did not provide a reason for the shortage.
- Mylan (Viatris) has imatinib tablets available.
- Novartis has Gleevec tablets available.
- Sun discontinued imatinib tablets in December 2024.
- Teva did not provide a reason for the shortage.
- Upsher-Smith did not provide a reason for the shortage.

Available Products

- Gleevec oral tablet, Novartis, 100 mg, bottle, 90 count, NDC 00078-0401-34
- Gleevec oral tablet, Novartis, 400 mg, bottle, 30 count, NDC 00078-0649-13
- Imatinib mesylate oral tablet, Chartwell, 100 mg, bottle, 90 count, NDC 62135-0658-90
- Imatinib mesylate oral tablet, Chartwell, 400 mg, bottle, 90 count, NDC 62135-0659-30
- Imatinib mesylate oral tablet, Major, 100 mg, unit-dose blister pack, 30 count, NDC 00904-6901-04
- Imatinib mesylate oral tablet, Mylan (Viatris), 100 mg, bottle, 90 count, NDC 00378-2245-77
- Imatinib mesylate oral tablet, Mylan (Viatris), 100 mg, unit-dose blister pack, 30 count, NDC 42292-0043-03
- Imatinib mesylate oral tablet, Mylan (Viatris), 400 mg, bottle, 30 count, NDC 00378-2246-93
- Imatinib mesylate oral tablet, Mylan (Viatris), 400 mg, unit-dose blister pack, 30 count, NDC 42292-0044-03

Estimated Resupply Dates

- Apotex has imatinib tablets on back order and the company estimates a release date in late-May 2025.
- Major has imatinib 400 mg tablets in 30 count unit-dose packages on back order and the company estimates a release date of early-June 2025.
- Teva has imatinib tablets on back order and the company estimates a release date in early- to mid-July 2025.
- Upsher-Smith has imatinib tablets on allocation for primary customers.

Updated

Updated May 16, 2025 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 14, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.